NFLX
66
4
ADBE
49
3
TROW
34
7
CCL
51
4
ICE
55
2
EXPE
74
8
LEG
27
5
DFS
71
7
OXY
60
4
CMG
60
3
PLD
48
3
PX
62
3
EMR
59
5
NWSA
45
2
BLK
69
2
MTCH
35
4
LNC
58
9
ED
45
-4
EFX
44
-6
LUV
45
5
NFLX
66
4
ADBE
49
3
TROW
34
7
CCL
51
4
ICE
55
2
EXPE
74
8
LEG
27
5
DFS
71
7
OXY
60
4
CMG
60
3
PLD
48
3
PX
62
3
EMR
59
5
NWSA
45
2
BLK
69
2
MTCH
35
4
LNC
58
9
ED
45
-4
EFX
44
-6
LUV
45
5
Financhill
Back

Myriad Genetics 10K Form

Sell
50

MYGN
Myriad Genetics

Last Price:
26.45
Seasonality Move:
9.99%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2024-05-08 10Q MYGN/Myriad Genetics Quarterly
2023-11-07 10Q MYGN/Myriad Genetics Quarterly
2023-08-04 10Q MYGN/Myriad Genetics Quarterly
2023-05-04 10Q MYGN/Myriad Genetics Quarterly
2022-11-02 10Q MYGN/Myriad Genetics Quarterly
2022-08-05 10Q MYGN/Myriad Genetics Quarterly

Receive MYGN News And Ratings

See the #1 stock for the next 7 days that we like better than MYGN

MYGN Financial Statistics

Sales & Book Value

Annual Sales: $753.2M
Cash Flow: $-6.3M
Price / Cash Flow: 0
Annual Sales: $8.15
Price / Book: 3.25

Profitability

EPS (TTM): -1.81000
Net Income (TTM): $-155.2M
Gross Margin: $517M
Return on Equity: -20.96%
Return on Assets: -13.67%

Myriad Genetics Earnings Forecast

Key Myriad Genetics Financial Ratios

  • The Gross Profit Margin over the past 28 years for MYGN is 68.64%.
  • The Selling, General & Administrative Expenses for MYGN have been equal to 76.06% of Gross Profit Margin.
  • The Research & Development expenses have been 11.78% of Revenue.
  • The Interest Expense is -1.10% of Operating Income.
  • The Net Earning history of MYGN is -34.96% of Total Revenues.
  • Per Share Earnings over the last 28 years have been positive in 14 years.

Myriad Genetics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: MYGN
CUSIP: 62855J
Website: myriad.com

Debt

Debt-to-Equity Ratio: 0.05
Current Ratio: 1.96
Quick Ratio: 1.44

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 94.31

MYGN Technical Analysis vs Fundamental Analysis

Sell
50
Myriad Genetics (MYGN) is a Sell

Is Myriad Genetics a Buy or a Sell?

  • Myriad Genetics stock is rated a Sell
    The current Myriad Genetics [MYGN] share price is $26.47. The Score for MYGN is 50, which is 0% below its historic median score of 50, and infers higher risk than normal.